Optimizing administration of epidermal growth factor receptor-targeted agents in the treatment of colorectal cancer.
The monoclonal antibodies against the epidermal growth factor receptor (EGFR) are active in patients with metastatic colorectal cancer (CRC; mCRC). This activity has been shown initially in irinotecan- and chemotherapy-refractory mCRC. The correlation of rash after EGFR inhibitors and activity has led to the concept of the dose until rash study. Clinical trials evaluating this concept are ongoing. However, many unresolved challenges remain regarding this question. New challenges include the development of the most optimal schedule of the EGFR inhibitors and the evaluation of their role in less advanced stages and in the preoperative treatment of liver metastases of CRC.
Van Cutsem
Eric
E
Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium. eric.vancutsem@uz.kuleuven.ac.be
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D018849:Controlled Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D016503:Drug Delivery Systems; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D019990:Perioperative Care; D012867:Skin / Q000187:drug effects / Q000473:pathology
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D066246:ErbB Receptors